Literature DB >> 20962532

Detection of Bet v1, Bet v2 and Bet v4 specific IgE antibodies in the sera of children and adult patients allergic to birch pollen: evaluation of different IgE reactivity profiles depending on age and local sensitization.

A Sekerková1, M Poláčková.   

Abstract

BACKGROUND: Birch pollen belongs to the major allergen triggers in the spring season in Europe. Our rapidly expanding knowledge of the allergenic molecules enables us to better recognize the individual differences between the reactivity of specific IgE antibodies of individual patients and allergic populations living in various regions of the world.
METHOD: In a group of birch pollen-allergic patients living in the Czech Republic (107 children, 71 adults) we detected the presence of Bet v1, Bet v2 and Bet v4 specific IgE antibodies.
RESULTS: Bet v1 specific IgE antibodies were identified in most patients without any significant differences between children and adults. Bet v2 positivity was found more frequently in the group of children than in adults (p = 0.02). In most adult patients Bet v1 monospecificity was more expressed as compared to the pediatric group. More allergic subjects reacted against minor birch allergens in the pediatric group (p = 0.02). Specific IgE antibodies against Bet v1 were not detected in 10% of the tested patients. In this group, 5% of birch pollen-allergic patients were found to not have specific IgE antibodies against any of the tested recombinant allergens.
CONCLUSION: The investigation of specific IgE antibodies against Bet v1, Bet v2 and Bet v4 demonstrated that the specificity of allergen-induced IgE antibodies in birch pollen-allergic individuals is dependent not only on the region in which a patient lives but also on age. Especially in children, there is an increase in the number of allergic subjects who do not react exclusively against the major allergen. The question is whether some allergen-specific IgE antibodies will disappear depending on age or on the contrary whether their synthesis will be increased.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962532     DOI: 10.1159/000321819

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

1.  Bet v 1 from birch pollen is a lipocalin-like protein acting as allergen only when devoid of iron by promoting Th2 lymphocytes.

Authors:  Franziska Roth-Walter; Cristina Gomez-Casado; Luis F Pacios; Nadine Mothes-Luksch; Georg A Roth; Josef Singer; Araceli Diaz-Perales; Erika Jensen-Jarolim
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

Review 2.  Tree pollen allergens-an update from a molecular perspective.

Authors:  C Asam; H Hofer; M Wolf; L Aglas; M Wallner
Journal:  Allergy       Date:  2015-08-06       Impact factor: 13.146

3.  Clinical Significance of Component Allergens in Fagales Pollen-Sensitized Peanut Allergy in Korea.

Authors:  Kyung Hee Park; Young Woong Son; Sang Chul Lee; Kyunguk Jeong; Da Woon Sim; Hye Jung Park; Sooyoung Lee; Jae Hyun Lee; Jung Won Park
Journal:  Allergy Asthma Immunol Res       Date:  2016-11       Impact factor: 5.764

4.  Allergen extracts and recombinant proteins: comparison of efficiency of in vitro allergy diagnostics using multiplex assay on a biological microchip.

Authors:  Olga Smoldovskaya; Guzel Feyzkhanova; Alla Arefieva; Sergei Voloshin; Olga Ivashkina; Yuriy Reznikov; Alla Rubina
Journal:  Allergy Asthma Clin Immunol       Date:  2016-03-13       Impact factor: 3.406

Review 5.  Pollen Allergens for Molecular Diagnosis.

Authors:  Isabel Pablos; Sabrina Wildner; Claudia Asam; Michael Wallner; Gabriele Gadermaier
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

6.  Production and Use of Recombinant Profilins Amb a 8, Art v 4, Bet v 2, and Phl p 12 for Allergenic Sensitization Studies.

Authors:  Beata Cudowska; A Brenda Kapingidza; Magdalena Pawłowicz; Agnieszka Pampuch; Noah Hyduke; Swanandi Pote; Caleb R Schlachter; Dariusz M Lebensztejn; Maksymilian Chruszcz; Krzysztof Kowal
Journal:  Molecules       Date:  2020-01-16       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.